Safety, efficacy and pharmacokinetics of humanized anti-CD52 monoclonal antibody alemtuzumab in Japanese patients with relapsed or refractory B-cell chronic lymphocytic leukemia
暂无分享,去创建一个
M. Ogura | K. Tobinai | K. Ishizawa | C. Nakaseko | S. Chiba | N. Fukuhara | Y. Sunaga | A. Okamoto | Yoshinori Sunaga